Mode
Text Size
Log in / Sign up

Prostatic incidental uptake on FDG PET/CT has a 1.7% prevalence with 21.3% malignancy riskNew data helps doctors identify prostate cancer risks on scans

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that focal or peripheral PIU with higher SUVmax and advanced age may indicate a higher risk of malignancy.

This meta-analysis of 24 studies evaluates the prevalence and risk associated with prostatic incidental uptake (PIU) on [18F]FDG PET/CT and other radiotracers, such as somatostatin analogues. The study identifies a 1.7% prevalence of PIU specifically on [18F]FDG PET/CT scans. For cases requiring further evaluation or biopsy, the malignancy rate was reported at 21.3%.

When evaluating uptake with somatostatin analogues (SSA), the prevalence was higher at 4.5%. The analysis also identified specific predictors for malignant PIU, including higher mean age, higher SUVmax, and peripheral location. These factors suggest that certain imaging characteristics may correlate with a higher likelihood of malignancy.

The authors note limitations including the inclusion of only one study for SSA PET/CT data. They conclude that more well-designed studies are required to define clinical impact and prevalence with non-FDG tracers. Clinicians should use these findings to guide individualized correlation, particularly when uptake is focal or associated with elevated PSA.

How this fits prior evidence

This meta-analysis addresses a gap in characterizing the risk of prostatic incidental uptake (PIU) on various radiotracers. While prior coverage noted that arecoline may upregulate androgen receptor in prostate cancer cells, this study provides data on imaging findings and malignancy risks. It also relates to previous evidence regarding PSA-based screening for prostate cancer by providing specific metrics for identifying high-risk cases through PET/CT imaging.

When patients get a PET scan, doctors sometimes see spots of activity in the prostate that they call incidental uptake. It can be hard to tell if these spots are just normal tissue behavior or signs of cancer. This analysis looked at 24 studies to help clarify what those signals might mean for patients.

The data shows that while many scans show some activity, only a portion of those cases turn out to be cancer. For example, when using one type of tracer, the uptake was seen in 1.7% of cases, while another tracer showed it in 4.5%. When these spots were checked with a biopsy, about 59.7% were confirmed as cancer.

To help doctors decide which cases need more testing, researchers found specific clues. Factors like an older age, a higher intensity of the signal (SUVmax), and a location on the outer edge of the prostate make it more likely that a spot is cancerous. Because only one study was used for some tracers, more research is needed to fully understand how these scans work in every situation.

What this means for you:
Specific factors like age and scan location help doctors tell if a prostate scan shows cancer or just normal activity.

Common questions

What is incidental uptake in a prostate scan?

Incidental uptake refers to areas of activity found during a PET scan that are not the main focus. In this study, it was seen in 1.7% of cases using one tracer and 4.5% when using another. Doctors use these findings to determine if further tests, like a biopsy, are needed.

How often does an abnormal scan actually mean cancer?

The results show that the risk varies depending on the type of scan and follow-up. When doctors performed biopsies on these areas of interest, about 59.7% were confirmed as malignancy (cancer). This helps doctors decide which patients need more immediate attention.

What factors make a scan result more concerning?

Certain indicators help doctors predict if an area is likely to be cancer. These include the patient's older age, a higher signal intensity known as SUVmax, and a location on the outer edge (peripheral) of the prostate.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundProstatic incidental uptake (PIU) may have clinical relevance, and progress in molecular imaging is likely to increase its detection. This study aimed to provide updated pooled estimates of the prevalence and malignancy risk of PIU identified on [18F]FDG positron emission tomography/computed tomography (PET/CT) and on PET/CT scans using radiotracers other than [18F]FDG.MethodsA comprehensive search for studies on PIU was performed in two databases, screening all available literature up to 30 October 2025. Only original articles reporting PIU were included. A proportion meta-analysis was conducted on a patient-based analysis using a random-effects model to calculate pooled prevalence and malignancy rates. In addition, several variables were evaluated as potential predictors of malignant PIU.ResultsTwenty-four studies met the inclusion criteria. PET/CT was performed with [18F]FDG in 23 studies and with radiolabeled somatostatin analogues (SSA) in one study. The pooled prevalence of PIU was 1.7% for [18F]FDG PET/CT, whereas the prevalence observed in the single eligible SSA PET/CT study was 4.5%. The pooled malignancy rates among PIU cases that underwent further evaluation or biopsy were 21.3% and 59.7%, respectively; no malignant lesions were reported in the SSA study. Malignant PIUs showed a higher mean age and a higher mean SUVmax compared with benign PIUs. A peripheral location of PIU emerged as a predictor of malignancy.ConclusionsPIU is detected in approximately 1.7% of [18F]FDG PET/CT scans in men and is associated with a relevant risk of malignancy. Accordingly, PIU should prompt individualized clinical correlation, particularly when uptake is focal, peripherally located, or associated with elevated PSA or other suspicious prostate-directed findings. More well-designed studies are required to better define the clinical impact of PIU and to determine its prevalence and clinical relevance when using PET tracers other than [18F]FDG.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.